BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAK7. A total of 1 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,403,217 | -7.3% | 4,445,000 | -5.9% | 0.01% | 0.0% |
| Q2 2023 | $4,749,060 | +208.5% | 4,724,000 | +220.1% | 0.01% | +250.0% |
| Q1 2023 | $1,539,477 | +0.9% | 1,476,000 | +3.9% | 0.00% | -33.3% |
| Q4 2022 | $1,525,876 | -32.0% | 1,420,000 | -37.1% | 0.00% | -25.0% |
| Q3 2022 | $2,243,000 | -0.1% | 2,259,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $2,245,000 | -1.3% | 2,259,000 | -0.5% | 0.00% | +33.3% |
| Q1 2022 | $2,274,000 | -14.0% | 2,271,000 | -10.3% | 0.00% | -25.0% |
| Q4 2021 | $2,643,000 | +4.0% | 2,533,000 | -0.3% | 0.00% | 0.0% |
| Q3 2021 | $2,542,000 | -19.5% | 2,540,000 | -19.4% | 0.00% | -20.0% |
| Q2 2021 | $3,158,000 | – | 3,152,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADVENT CAPITAL MANAGEMENT /DE/ | 70,652,000 | $71,212,000 | 1.38% |
| SHENKMAN CAPITAL MANAGEMENT INC | 14,821,000 | $14,947,000 | 1.36% |
| AQR Arbitrage LLC | 21,650,000 | $21,800,000 | 0.61% |
| Worth Venture Partners, LLC | 708,000 | $714,000 | 0.27% |
| LOOMIS SAYLES & CO L P | 2,366,716 | $197,478,000 | 0.24% |
| MACKAY SHIELDS LLC | 24,500,000 | $24,670,000 | 0.23% |
| CAMDEN ASSET MANAGEMENT L P /CA | 2,500,000 | $2,505,000 | 0.10% |
| PALISADE CAPITAL MANAGEMENT, LP | 2,429,000 | $2,442,000 | 0.06% |
| Alberta Investment Management Corp | 5,500,000 | $5,545,000 | 0.05% |
| EDMOND DE ROTHSCHILD HOLDING S.A. | 1,900,000 | $1,913,000 | 0.04% |